NL301017I1 - Combinatie van tropicamide; fenylefrine, desgewenst in de vorm van fenylefrine hydrochloride; en lidocaïne, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, bij voorkeur lidocaïne hydrochloride - Google Patents

Combinatie van tropicamide; fenylefrine, desgewenst in de vorm van fenylefrine hydrochloride; en lidocaïne, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, bij voorkeur lidocaïne hydrochloride

Info

Publication number
NL301017I1
NL301017I1 NL301017C NL301017C NL301017I1 NL 301017 I1 NL301017 I1 NL 301017I1 NL 301017 C NL301017 C NL 301017C NL 301017 C NL301017 C NL 301017C NL 301017 I1 NL301017 I1 NL 301017I1
Authority
NL
Netherlands
Prior art keywords
optionally
phenylephrine
hydrochloride
lidocaine
tropicamide
Prior art date
Application number
NL301017C
Other languages
English (en)
Other versions
NL301017I2 (nl
Original Assignee
Thea Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thea Lab filed Critical Thea Lab
Publication of NL301017I1 publication Critical patent/NL301017I1/nl
Publication of NL301017I2 publication Critical patent/NL301017I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
NL301017C 2005-03-09 2019-10-30 Combinatie van tropicamide; fenylefrine, desgewenst in de vorm van fenylefrine hydrochloride; en lidocaïne, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, bij voorkeur lidocaïne hydrochloride NL301017I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0502357A FR2882930B1 (fr) 2005-03-09 2005-03-09 Nouvelles compositions ophtalmologiques et leur mode d'utilisation
PCT/FR2006/000528 WO2006095095A1 (fr) 2005-03-09 2006-03-09 Compositions ophtalmologiques et leur mode d’utilisation

Publications (2)

Publication Number Publication Date
NL301017I1 true NL301017I1 (nl) 2019-11-06
NL301017I2 NL301017I2 (nl) 2020-04-30

Family

ID=35058756

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301017C NL301017I2 (nl) 2005-03-09 2019-10-30 Combinatie van tropicamide; fenylefrine, desgewenst in de vorm van fenylefrine hydrochloride; en lidocaïne, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, bij voorkeur lidocaïne hydrochloride

Country Status (26)

Country Link
US (2) US20080194649A1 (nl)
EP (1) EP1858481B1 (nl)
JP (1) JP2008532985A (nl)
KR (1) KR20070111501A (nl)
CN (1) CN101151018A (nl)
CA (1) CA2598503C (nl)
CY (2) CY1121865T1 (nl)
DK (1) DK1858481T3 (nl)
ES (1) ES2728071T3 (nl)
FR (1) FR2882930B1 (nl)
HR (1) HRP20191044T1 (nl)
HU (1) HUE043668T2 (nl)
IL (1) IL185197A0 (nl)
LT (2) LT1858481T (nl)
LU (1) LUC00136I2 (nl)
MA (1) MA29269B1 (nl)
MX (1) MX2007010295A (nl)
NL (1) NL301017I2 (nl)
NO (2) NO339793B1 (nl)
PL (1) PL1858481T3 (nl)
PT (1) PT1858481T (nl)
RU (1) RU2392925C2 (nl)
SI (1) SI1858481T1 (nl)
TN (1) TNSN07343A1 (nl)
TR (1) TR201908487T4 (nl)
WO (1) WO2006095095A1 (nl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8602959B1 (en) * 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
WO2012111029A2 (en) * 2011-02-18 2012-08-23 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
ITPA20110004A1 (it) * 2011-02-23 2012-08-24 Francesco Paolo Montalto Iniezione intracamerulare per anestesia e dilatazione pupillare (midriasi).
CN103159672A (zh) * 2012-07-16 2013-06-19 湖南尔文生物科技有限公司 一种托品酰胺的制备方法
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
RU2525512C1 (ru) * 2013-03-28 2014-08-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ медикаментозного расширения ригидного зрачка перед проведением факоэмульсификации
JP2016532723A (ja) * 2013-10-03 2016-10-20 インプリミス・ファーマシューティカルズ・インコーポレイテッドＩｍｐｒｉｍｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法
CN105213418B (zh) * 2015-11-11 2019-01-22 中国人民解放军第四军医大学 一种眼科术前用复方滴眼液及其制备方法
EP3503873A4 (en) * 2016-08-25 2020-04-15 Harrow IP, LLC EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF
RU2649534C1 (ru) * 2017-05-10 2018-04-03 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ анестезии при факоэмульсификации катаракты
RU2662423C1 (ru) * 2017-07-26 2018-07-25 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ проведения обезболивания при выполнении витреоретинальных операций

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026323A (en) * 1960-03-22 1962-03-20 Rubin J Schacter Salts of tribasic acids
JPH0780760B2 (ja) * 1986-07-28 1995-08-30 ライオン株式会社 安定化されたフエニレフリン系液剤
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
US6319240B1 (en) * 1999-05-25 2001-11-20 Iomed, Inc. Methods and apparatus for ocular iontophoresis
AU2249701A (en) * 1999-11-12 2001-06-06 David Bernstein Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
JP4150846B2 (ja) * 2001-03-28 2008-09-17 参天製薬株式会社 ステロイドを有効成分とする網脈絡膜疾患治療剤
US20040013729A1 (en) * 2002-07-18 2004-01-22 Buono Lawrence M. Single-drop multiple-agent composition for topical delivery to the eye
CN103143022A (zh) * 2002-07-30 2013-06-12 奥默罗斯公司 眼科冲洗液及方法

Also Published As

Publication number Publication date
EP1858481B1 (fr) 2019-05-08
LT1858481T (lt) 2019-07-10
FR2882930B1 (fr) 2009-03-27
HRP20191044T1 (hr) 2019-09-06
LTPA2019017I1 (lt) 2019-12-10
CA2598503C (fr) 2014-01-28
NL301017I2 (nl) 2020-04-30
WO2006095095A1 (fr) 2006-09-14
US20120220637A1 (en) 2012-08-30
PL1858481T3 (pl) 2019-09-30
NO20074850L (no) 2007-09-24
NO2017008I2 (no) 2017-03-24
TR201908487T4 (tr) 2019-07-22
JP2008532985A (ja) 2008-08-21
LUC00136I2 (nl) 2021-02-12
CN101151018A (zh) 2008-03-26
US20080194649A1 (en) 2008-08-14
CA2598503A1 (fr) 2006-09-14
LUC00136I1 (nl) 2019-11-04
CY2019042I2 (el) 2020-05-29
FR2882930A1 (fr) 2006-09-15
NO2017008I1 (no) 2017-03-24
CY1121865T1 (el) 2020-05-29
TNSN07343A1 (fr) 2008-12-31
ES2728071T3 (es) 2019-10-22
KR20070111501A (ko) 2007-11-21
MA29269B1 (fr) 2008-02-01
MX2007010295A (es) 2007-12-11
US9289399B2 (en) 2016-03-22
SI1858481T1 (sl) 2019-08-30
NO339793B1 (no) 2017-01-30
HUE043668T2 (hu) 2019-08-28
IL185197A0 (en) 2008-01-06
BRPI0607416A2 (pt) 2009-09-08
EP1858481A1 (fr) 2007-11-28
RU2007137115A (ru) 2009-04-20
PT1858481T (pt) 2019-06-14
CY2019042I1 (el) 2020-05-29
DK1858481T3 (da) 2019-06-03
RU2392925C2 (ru) 2010-06-27

Similar Documents

Publication Publication Date Title
NL301017I1 (nl) Combinatie van tropicamide; fenylefrine, desgewenst in de vorm van fenylefrine hydrochloride; en lidocaïne, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, bij voorkeur lidocaïne hydrochloride
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I2 (nl) crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301042I2 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NL301261I2 (nl) Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301106I1 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301065I2 (nl) Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NL300913I2 (nl) Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride
NL300863I2 (nl) Palbociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
FIC20230040I1 (fi) Koostumus käsittäen: sedatsuridiinia tai tämän farmaseuttisesti hyväksyttävää suolaa; ja desitabiinia.
NL300946I2 (nl) Brexpiprazole, desgewenst in de vorm van een zout
NL301104I1 (nl) Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL301209I2 (nl) capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL300889I1 (nl) Trifluridine in combinatie met tipiracil of een zout van tipiracil, zoals tipiracilhydrochloride
NL301067I2 (nl) Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301199I2 (nl) Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide
NO2018029I1 (no) Alogliptin i kombinasjon med metformin, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
NL301230I2 (nl) Mitapivat, dan wel een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder mitapivatsulfaat
NL301202I2 (nl) Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL300895I2 (nl) Rolapitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van rolapitant hydrochloridemonohydraat
NL300865I2 (nl) Eluxadoline of een farmaceutisch aanvaardbaar zout ervan
NL300872I2 (nl) Combinatie van empagliflozine en linagliptine of een farmaceutisch aanvaardbaar zout daarvan
NO2022022I1 (no) Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate